Explainable AI reveals changes in skin microbiome composition linked to phenotypic differences.

Journal: Scientific reports
PMID:

Abstract

Alterations in the human microbiome have been observed in a variety of conditions such as asthma, gingivitis, dermatitis and cancer, and much remains to be learned about the links between the microbiome and human health. The fusion of artificial intelligence with rich microbiome datasets can offer an improved understanding of the microbiome's role in human health. To gain actionable insights it is essential to consider both the predictive power and the transparency of the models by providing explanations for the predictions. We combine the collection of leg skin microbiome samples from two healthy cohorts of women with the application of an explainable artificial intelligence (EAI) approach that provides accurate predictions of phenotypes with explanations. The explanations are expressed in terms of variations in the relative abundance of key microbes that drive the predictions. We predict skin hydration, subject's age, pre/post-menopausal status and smoking status from the leg skin microbiome. The changes in microbial composition linked to skin hydration can accelerate the development of personalized treatments for healthy skin, while those associated with age may offer insights into the skin aging process. The leg microbiome signatures associated with smoking and menopausal status are consistent with previous findings from oral/respiratory tract microbiomes and vaginal/gut microbiomes respectively. This suggests that easily accessible microbiome samples could be used to investigate health-related phenotypes, offering potential for non-invasive diagnosis and condition monitoring. Our EAI approach sets the stage for new work focused on understanding the complex relationships between microbial communities and phenotypes. Our approach can be applied to predict any condition from microbiome samples and has the potential to accelerate the development of microbiome-based personalized therapeutics and non-invasive diagnostics.

Authors

  • Anna Paola Carrieri
    IBM Research UK, Sci-Tech Daresbury, Warrington, UK.
  • Niina Haiminen
    T.J. Watson Research Center, IBM Research, Yorktown Heights, NY, 10598, USA.
  • Sean Maudsley-Barton
    The Hartree Centre, Sci-Tech Daresbury, IBM Research, Daresbury, WA4 4AD, UK.
  • Laura-Jayne Gardiner
    IBM Research UK, Sci-Tech Daresbury, Warrington, UK. Laura-Jayne.Gardiner@ibm.com.
  • Barry Murphy
    Unilever Research & Development, Port Sunlight, CH63 3JW, UK.
  • Andrew E Mayes
    Unilever Research and Development, Sharnbrook, MK44 1LQ, UK.
  • Sarah Paterson
    Unilever Research & Development, Port Sunlight, CH63 3JW, UK.
  • Sally Grimshaw
    Unilever Research & Development, Port Sunlight, CH63 3JW, UK.
  • Martyn Winn
    Scientific Computing Department, STFC Daresbury Lab, Daresbury, WA4 4AD, UK.
  • Cameron Shand
    The Hartree Centre, Sci-Tech Daresbury, IBM Research, Daresbury, WA4 4AD, UK.
  • Panagiotis Hadjidoukas
    IBM Research - Zurich, Saumerstrasse 4, 8803, Rueschlikon, Switzerland.
  • Will P M Rowe
    University of Birmingham, Birmingham, UK.
  • Stacy Hawkins
    Unilever Research & Development, Trumbull, CT, 06611, USA.
  • Ashley MacGuire-Flanagan
    Unilever Research & Development, Trumbull, CT, 06611, USA.
  • Jane Tazzioli
    Unilever Research & Development, Trumbull, CT, 06611, USA.
  • John G Kenny
    Institute of Integrative Biology, The University of Liverpool, The Bioscience Building, Liverpool, L697ZB, UK.
  • Laxmi Parida
    Computational Genomics, IBM Research, Yorktown Heights, NY, USA.
  • Michael Hoptroff
    Unilever Research & Development, Port Sunlight, CH63 3JW, UK.
  • Edward O Pyzer-Knapp
    IBM Research U.K. , Hartree Centre, Daresbury WA4 4AD , United Kingdom.